A B S T R A C T We have studied the interaction between thrombin and washed, human platelets using prostacyclin, a reversible inhibitor ofplatelet secretion. The effect of thrombin is limited to those reactions that are not inhibited by an increased concentration ofplatelet cyclic adenosine 3',5'-monophosphate, because prostacyclin is a potent inducer of the latter. Prostacyclin-treated platelets were briefly (15-30 s) exposed to low concentrations of human thrombin (0.01-0.2 U/ml). After removal of the prostacyclin and thrombin, the platelets were incubated with fresh thrombin. Although they had not undergone the release reaction after the first thrombin incubation, these platelets had a diminished capacity to secrete [3H]serotonin when exposed to thrombin the second time. Refractoriness was concentration dependent: the higher the initial thrombin concentration, the greater the degree of inhibition of serotonin secretion on subsequent thrombin exposure. Inhibition was closely related to the ability of thrombin to induce platelet secretion and not to its esterase or fibrinogen clotting activity. Diisopropyl fluorophosphate-inactive thrombin did not induce refractoriness. Refractoriness to thrombin did not increase when the time of the initial incubation with thrombin was lengthened, nor was it reversible.
INTRODUCTION
Thrombin, a blood coagulation factor with proteinase activity, is also capable of initiating platelet secretion (1) . Because it stimulates platelet secretion at concentrations that are generated physiologically (1-2 nM), it is likely to be important in the initiation ofthe platelet thrombus formed in response to vascular injury (2, 3) . The mechanism by which thrombin stimulates platelet secretion is unknown. Recent evidence suggests that thrombin initiates the platelet release reaction' through a different pathway from that of other mediators of secretion (4, 5) . Most agents known to induce secretion require formation of platelet prostaglandin endoperoxides and release of adenosine diphosphate. Thrombin, however, does not.
Equilibrium binding of thrombin to the platelet surface appears to be the first step in this pathway (6) (7) (8) (9) (10) . Thrombin binding is specific, saturable, and reversible (9) . The precise correlation that has been demonstrated between the amount of thrombin bound to the platelet and the extent of secretion suggests that binding may be ofphysiological importance (11) . However, although it may be the necessary first step in the secretory pathway, binding in itselfis insufficient to induce the release reaction. This is indicated by the fact that thrombin inactivated at its serine center and native thrombin bind identically to platelets, whereas only the native form induces secretion (7, 12) .
The specific reactions that follow thrombin binding have not been characterized. Although thrombin stimulates a variety of metabolic changes in platelets (13) (14) (15) (16) , these reactions occur in response to most agonists that stimulate the release reaction. One reason for the paucity of information on the sequence of events that takes place after thrombin binding is the rapidity with which secretion occurs. Because in human platelets secretion takes place in <1 min (17) , it has been dif-ficult to separate the unique effects of thrombin on platelets from the general changes associated with secretion. By incubating platelets with prostacyclin (PGI2),2 a reversible inhibitor of secretion, we have been able to study the presecretory effects of thrombin on platelets. In this report, we describe the nature of some ofthese effects and how they relate to subsequent platelet secretion.
METHODS
Preparation of platelets, thrombin, and other materials. Platelets were prepared from freshly drawn blood according to the method of Baenziger and Majerus (18) .
Human alpha and gamma thrombin were prepared as described previously (11, 19, 20 [1251] thrombin was used the same day of preparation and the DIP-thrombin over a period of 3 wk. Acid soluble collagen was a gift from Mr. Heinz Scheuenstuhl. It was prepared from bovine achilles tendon, Type 1, purchased from Sigma Chemical Co. Wheat germ lectin was prepared by affinity chromatography using ovamucoid-Sepharose (Pharmacia Fine Chemicals Inc.) as described by LeVine et al. (21) . PGI2 was synthesized by K. C. Nicolau of the University of Pennsylvania (22) , and kindly supplied by Dr. J. Bryan Smith ofThomas Jefferson University, Philadelphia, Pa. Rabbit antihuman thrombin antibody and F(ab')2 fragments were prepared as described previously (8) .
Preincubation of platelets with thrombin. Platelets (2-4 x 109/ml) prelabeled with pH]serotonin (7) , were suspended in 0.5 ml ofbuffer containing 0.14 M NaCl, 0.015 M Na2HPOJ NaH2PO4, 0.005 M glucose, 0.5% bovine serum albumin (fraction 1, Sigma Chemical Co.), 0.002 M EDTA, and 2 uM imipramine (Sigma Chemical Co.), pH 7.4. PGI2(20 nM final concentration) was added in a 1:100 dilution for 1 min before the addition ofthrombin (0.01-0.2 U/ml). Platelets and thrombin were incubated at room temperature for 15-30 s, then anti-thrombin F(ab')2 fragments were added in a concentration that completely inactivated the thrombin within 30 The platelet pellet was resuspended in isotonic buffer (0.14 M NaCl, 0.015 M Na2HPO4/NaH2PO4, 0.005 M glucose, pH 7.4). The platelet concentration was then determined with a hematocytometer (23) .
Samples of platelets (5 x 107), previously exposed to alpha thrombin (or its derivatives, DIP-or gamma thrombin), were suspended in 0. Thrombin binding. Platelets (0.4 ml) were centrifuged through a mixture of n-butyl phthalate and type A Apiezon oil (James G. Biddle Co., Plymouth Meeting, Pa.), and the radioactivity contained in the platelet pellet determined in a gamma scintillation spectrometer (24) . Net thrombin bound and nonspecific binding were determined as described previously (7).
Platelet secretion. Platelets (0.2 ml) were membrane filtered and the retained pH]serotonin was measured in a liquid scintillation counter. Gross counts per minute were corrected for 125I using 1251 standards which were counted by beta and gamma scintillation spectrometry (11) .
RESULTS
Inhibition of thrombin-induced platelet secretion of
[3H]serotonin by PGI2. To determine the effects of thrombin on platelets apart from those changes associated with the release reaction, it was necessary to develop a technique by which platelets could be incubated with thrombin without subsequent secretion. Furthermore, it was required that the inhibition be reversible so that platelet responsiveness could be studied after the removal of thrombin. PGI2, an inhibitor of platelet aggregation (25) , appeared to be a likely agent because its effects are rapidly reversible (26, 27) . Platelets incubated for 1 min with 20 nM PGI2 did not secrete pH]serotonin when exposed to thrombin concentrations that would normally induce 10-60% secretion ( Fig. 1 ). In addition, we determined that once PGI2-induced inhibition was reversed, the platelets responded normally to thrombin (data not shown).
Effect of preincubating platelets with thrombin on their secretory response to subsequent thrombin stimulation. As shown in Fig. 2 That this effect was not due to centrifugation of the platelets or to the PGI2 was indicated by the fact that control platelets were treated identically except for the initial exposure to thrombin. Similarly, inhibition did not result from platelet secretion after the first thrombin incubation, because <1 %ofthe [3H] serotonin appeared in the supemate after centrifugation. Imipramine was included in the initial incubation mixture to block reuptake of [3H]serotonin (28) . Anti-thrombin F(ab')2 fragments were added to the platelets 15 s after the thrombin to limit the duration of its effect. When thrombin was preincubated with anti-thrombin F(ab')2 fragments for 30 s before its addition to platelets, a 90% decrease in its inhibitory effect on subsequent platelet secretion was seen.
It is interesting that platelets preincubated with PGI2 before thrombin exposure did not secrete [31H]serotonin once the effect of PGI2 had been reversed and the thrombin removed. It should be noted also that the incubation period with thrombin (15-30 s) was limited to the time necessary for thrombin-induced platelet secretion (17) . Thus, although thrombin binding was normal in the presence of PGI2 (data not shown), after binding, the secretory stimulus did not progress to a point that resulted in the release reaction once PGI2 inhibition was reversed.
Effect of modification ofnative thrombin on its reaction with PGI2-treated platelets. Next, we used modified thrombins to determine the relationship between their ability to induce platelet secretion and their effect on PGI2-treated platelets. Platelets were preincubated with PGI2, then with thrombin inactivated at its serine-active site with iPr2PF(DIP-thrombin). Thrombin modified in this way binds to platelets identically to native thrombin but does not cause the release reaction (7) . As shown in Fig. 3 Gamma thrombin, a product of limited tryptic proteolysis of alpha thrombin, has -O.1% of the fibrinogen clotting activity of native thrombin, 1% of the platelet release-inducing activity, and full esterase activity (5, 20) . When either alpha or gamma thrombin was preincubated with PGI2-treated platelets at equivalent concentrations based on the ability to induce platelet secretion, there was complete inhibition of secretion on reexposure to thrombin (Table I ). The platelets were preincubated with a concentration of alpha or gamma thrombin sufficient to give 50% secretion of [3H]serotonin in the absence of PGI2. On a molar basis the concentration of gamma thrombin was 75-fold higher than the alpha thrombin and had only 2% of the clotting activity. Apparently the inhibition of secretion that resulted from thrombin preincubation was specifically related to its ability to induce secretion and not to its esterase activity. Nor does it appear to be a nonspecific proteolytic effect, because an equivalent inhibitory effect was seen at a 50-fold lower concentration based on the ability to cleave fibrinogen.
Effect of increasing the thrombin concentration on platelet secretion inhibited by prior incubation with thrombin. Next, we determined whether the platelet refractoriness to thrombin could be overcome by increasing the thrombin concentration with which the platelets were stimulated the second time. As shown in Fig. 4 , a fourfold higher concentration of thrombin was required to achieve the same extent of serotonin secretion (50%) as for platelets not previously exposed to thrombin. When the time of preincubation of platelets with thrombin was increased from 15-30 to 300 s, no additional increase in the concentration of thrombin was necessary to achieve secretion (Fig. 4) . The same result was obtained when a concentration of thrombin that resulted in 50% inhibition of secretion was used. There was no increase in the percentage of inhibition when the preincubation was lengthened to 300 s. Specificity ofinhibition ofplatelet secretion itiduced by thrombin preincubation. The effect of thrombin pretreatment on the release reaction induced by other agonists was studied also. WVhen collageni, wheat germn agglutinin, or the calcium ionophore A23187 was used to stimulate platelet secretion, there was little difference in the extent of [3H]serotonin release whether or not the platelets were first preincubated with thrombini (Table II) . The conicentration ofthrombiin used, 0.19 U/ ml, however, resulted in 90% inhibition of thrombininduced secretion. A small, but coonsistenit, inhil)ition of A23187-induced secretion was seen oni several occasions. The significance ofthis is unknown. This marked refractoriness to thrombin but not other platelet stimuli suggests that the effect of thrombin preincubation is specific.
Binding of [125I]thrombin to platelets previously exposed to thrombin. To determine whether the refactoriness of platelets to thrombin was because of an effect on thrombin binding, the following experiment was performed: Platelets were preincubated with a concentration of thrombin (0.2 U/ml) which resulted in 93% inhibition of serotonin secretion (platelets not pretreated with thrombin showed 59% secretion; thrombin-pretreated platelets, 7% secretion). The thrombin was removed by centrifugation and both binding of [1251] thrombin to the resuspended platelets and extent of serotonin secretion were measured. As shown in Fig. 5 , for the same amount of thrombin bound, a marked decrease was seen in serotonin secretion in those platelets preexposed to thrombin compared to control platelets. Approximately four times as much bound thrombin was required for 40% serotonin secretion in thrombin-pretreated platelets. Thus, the inhibitory effect on platelet secretion that followed thrombin pretreatment was because of alteration of a step subsequent to thrombin binding to platelets.
Duration of inhibition of platelet secretion induced by thrombin preincubation. In many tissues, reversible desensitization to agonist stimulation has been observed (29) . We examined the possibility that the inhibition of platelet secretion we had observed was related to a reversible desensitization of the platelets to thrombini. Platelets were preincubated with thrombin in the presence of PGI2. Then, thrombin was inactivated with anti-thromiibin F(ab')2 fragments, and both the thrombin and PGI2 were removed after centrifugation of the platelets. The resuspended plate- Collagen (16 ,ug/ml) 17 21 Collagen (40 ug/ml) 34 
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Wheat germ lectiin (300 ,tg/ml) (30, 31) . However, the step in the secretory pathway at which the platelets become modified has not been established. We have studied the interaction between PGI2-treated platelets and thrombin to determine the effects ofthrombin on platelets before secretion. These platelets compared to those not prestimulated with thrombin exhibit a marked decrease in serotonin secretion. That refractoriness to thrombin stimulation is related to an alteration of a step in the secretory pathway rather than a nonphysiological effect is indicated by the following observations. First, the amount of thrombin used to induce refractoriness was not in excess of that necessary to induce secretion. Second, this effect was not due to prolonged exposure of the platelets to thrombin, because the incubation was limited to the time necessary to induce the release reaction. Third, the secretory and inhibitory effects of thrombin on platelets are both dose dependent. The higher the thrombin concentration, the greater the degree of secretion or inhibition. Fourth, the capacity of thrombin to render the platelets refractory correlates closely with its ability to induce secretion. This is indirect evidence that the inhibitory effect on the platelet is not secondary to a nonspecific esterolytic or proteolytic action ofthrombin. Similarly, the mlarked discrepanicy between the platelet-secretory and fibrinogen-clotting activity ofthe gamiminla thronmbin stuggests that inhibition is not the result of an alteration of platelet fibrinogen. Fifth, the effect was specific for thrombin: platelet secretion induced by wheat germ atgglutinin, the ionlophore A23187, aindl collageni was relatively unaffected by previous exposure of the platelets to thrombin. In additioni, preincubation of PG12-treatted platelets with collageni hasino effect on either thromibin-or collageninduced platelet secretion.:1 (29) . The effect was seen after exposure ofthe platelets to thrombin for only 15-30 s. Although desensitization of parotid acinar cells to epinephrine after a 2-min exposure has been described (32), a longer incubation period is generally required. Also, desensitization generally increases with time: the longer the exposure of target cells to the agonist, the greater the degree of refractoriness to subsequent stimulation. This is not the case with thrombin and platelets. As much inhibition was seen after 15 s of exposure to thrombin as after 300 s. Also, inhibition was not reversed after the removal of thrombin and PGI2. Another difference between our findings and those of studies demonstrating desensitization is that frequently a correlation has been noted between desensitization and resensitization with a change in the number of receptors on the target cell. On the contrary, we observed that for the same amount of thrombin bound, there was less secretion in thrombin-pretreated platelets than control platelets. Thus, if refractoriness to thrombin is a result of desensitization, it differs in several respects from previously described examples.
Considerable evidence suggests that regulation of adenylate cyclase is an essential step in the platelet secretory pathway (33, 34) . Most (33, 34) . Reactions knowni to be inhibited by these secretory antagonists include hydrolysis ofarachadonic acid from platelet phospholipid, and phosphorylation of platelet proteins in response to thronribin (36, 37) . It is unlikely, therefore, that the refractoriness that results from the exposture of PGI2-treated platelets to thrombin is a restult of an effect on either of these reactions or on events that occ ur subseqluently.
Friedcmani anid Detwiler have shown that cyclic ANIP inhibits thrombin-induced platelet secretion in a com01-plex miiianner (38) . On the basis of kinetic studies of ATP secretion, they concluded that 1)oth the rate of the initial steps in secretion and the total amiiount of secretion were inhibited by drugs that elevate cyclic ANIP.
At low concenitrationis of prostaglandin E1 (PGEI), there wats both a delav ini the onset of secretion aind a prOlongationi in the timiie required for secretion, once iniitiatedl. At high PGE, conicentrattionis, complete inhibition of secretioni occurred. Our observations suggest the preseniee of at least one step in the secretory pathway betweeni thrombini binding aind( regtulation of a(lenlvate cvchlse. This step appears to be specific for thrombIin; it mav also be ani essential mechaniismii for tra.nsmiiittinig the signall that leads to the extrusioni of initracelltllular graniiular contenits.
